Modality
Degrader
MOA
C5i
Target
BCMA
Pathway
Lipid Met
ALLIPF
Development Pipeline
Preclinical
~Mar 2016
→ ~Jun 2017
Phase 1
Sep 2017
→ Feb 2027
Phase 1Current
NCT07104989
298 pts·IPF
2017-09→2025-12·Active
NCT04512720
2,982 pts·ALL
2021-05→2027-02·Not yet recruiting
3,280 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-12-104mo agoPh2 Data· IPF
2027-02-2211mo awayPh2 Data· ALL
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P1/2
Active
P1/2
Not yet…
Catalysts
Ph2 Data
2025-12-10 · 4mo ago
IPF
Ph2 Data
2027-02-22 · 11mo away
ALL
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07104989 | Phase 1/2 | IPF | Active | 298 | PFS |
| NCT04512720 | Phase 1/2 | ALL | Not yet recr... | 2982 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA | |
| Pexanesiran | United Therapeutics | Phase 1 | BCMA |